|Awarded On||August 16, 2017|
|Title||Patient-Derived Xenograft and Advanced in Vivo Models (PDX-AIM) Core Facility|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Michael Lewis|
|Cancer Sites||All Sites|
With a few exceptions, traditional cancer research using tumor-derived cell lines grown on plastic have failed to yield results that benefit cancer patients. There are many reasons for this failure. To circumvent these shortcomings, researchers have begun to use “patient-derived xenografts” (PDX), and other models in which human tumors are grown in living hosts, including the mouse and the fertilized chicken egg. Development of a Patient-Derived Xenograft and Advanced In Vivo Models (PDX-AIM) Core is a high priority for Baylor College of Medicine (BCM) and its affiliate, The Texas Children’s Hospital (TCH). BCM established a new PDX-AIM Core in 2016 jointly backed by the BCM Advanced Technol...